Project Term
–
Project Summary
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation of abnormal myeloid precursors and poor prognosis despite advances in treatment. Recent work using Rapid Extracellular Antigen Profiling (REAP) has shown that autoantibody responses can correlate with disease outcomes and immune dysregulation in cancer.
We will leverage a large, clinically annotated AML biobank containing patient demographics, genetic mutations, treatment history, and outcomes to identify autoantibody patterns associated with survival and clinical phenotypes.
Lay Abstract
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by clonal proliferation of abnormal myeloid precursors and poor prognosis despite advances in treatment.
We will apply Rapid Extracellular Antigen Profiling (REAP) systematically to AML cohorts with robust clinical annotation.
Aim 1: Learn the clinical course and standard of care in AML.
Aim 2: Annotate the AML biobank through retrospective EHR review.
Aim 3: Analyze REAP autoantibody profiles in AML.
Program
